Ensysce closes $7M public offering of common stock and warrants

Ensysce Biosciences, Inc.

Offered 1,800,876 shares (or pre-funded warrants) plus Series A-1/A-2 warrants at $3.887 per unit.
Gross proceeds ~$7M; net proceeds for clinical development and working capital.
H.C. Wainwright acted as exclusive placement agent for the offering.
Amended 210,085 existing warrants from $16.80-$187.20 to $3.637 per share at $0.125 per amended warrant.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Ensysce Biosciences, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $7.0 million (effective 2023-05-10).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $7.0 million
Effective: 2023-05-10

Exact text from the filing

In connection with the offering of the Shares, we entered into a definitive Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-017038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.